Observational study examines risks and benefits in a state-regulated psilocybin program, highlighting real-world safety and implementation outcomes.
Given the growing interest in psychedelic‐assisted therapies, questions remain about how such services perform outside controlled clinical trials. A new JAMA Network Open study offers an early look at the risks and benefits of Oregon's state‐regulated psilocybin program, which researchers describe as the first study of its kind in the nation.
No takes yet. Share an insight, caveat, or question.
Valerie A. Canady (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: